Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am SNDY long.
http://www.solosendoscopy.com/SNDY-ISO-13485-CE-Mark-Project-Schedule-July-2012.pdf
SNDY..For new people to read. This company is doing all the correct steps necessary to move this company to future growth for everyone.
SNDY is doing all the correct steps necessary to move it up to the next level. It takes time. Patience is the key.
This company is taking all the correct steps necessary to take it up to the next level. Read, research. Takes time, patience. News on their subsidiary company, is a huge step in the right direction.
All the news on PRTN is spectacular!
PRTN is the symbol. Not PRTNE.
Everyone don't forget the dividend that's coming.
PRTN decided not to add the letter E on the end of their symbol.
I agree ajurm. There has been a lot of accomplishments for SNDY. This company is taking it to the next level.
We are a outside group of investors. We have several ventures and projects. I an the only one who looks into IHub to see what people thoughts are in regards to certain stocks.
We are SNDY long. This company is doing all the right steps necessary for exceptional growth, for shareholders and the company. It takes time and patience.
Wishing everyone a great day.
On my side, our group is currently holding 40 million shares.
A group of private investors are buying up millions of shares. These shares are in strong, long, investors hands.
Ichase I I agree.
Why are you here?? It's pretty evident you don't like this stock . Even with all the FACTS you're still against it . Are you trying to short the stock?? Meaning you are betting against the stock?? Or, are you trying to get get the stock price low, so you can buy on the cheap?? Why did you even buy this stock??
The results of this post are quite impressive. This was posted in May. The news is going to be great over the next several months! Definately future growth for shareholders and the company
News!!!! MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
WOONSOCKET, R.I., May 16, 2012 /PRNewswire via COMTEX/ -- MultiCell Technologies, Inc. (MCET) is pleased to announce representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012 (http://meeting.cimt.eu), Europe's largest meeting dedicated to cancer immunotherapy research and development. CIMT 2012 will be held in May 23-25 in Mainz, Germany. The title of the poster presentation is: "Sharply discordant biological properties of synthetic noncoding dsRNA of different size: Translational opportunities in cancer." The poster presentation in the Enhancing Immunity session of the conference (poster number 078) will be made by Dr. Simona Bot, a consultant to the Company. The Company will present its findings during Poster Session I held on May 23rd, from 3:00-4:30 PM, and Poster Session II held on May 24th from 4:00-5:30 PM.
About MCT-465 and MCT-485
MCT-465 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented TLR3 signaling technology. MCT-465 and MCT 485 are in preclinical development, and are being investigated as prospective treatments for primary liver cancer and triple negative breast cancer.
The immune system is composed of two synergistic elements: the innate immune system and the adaptive immune system. Stimulation of the innate immune system through key receptors, plays a critical role in triggering the adaptive immune response stimulating T and B cells to produce antibodies. In cancer, this integrated defense system does not work well, resulting in suboptimal activation of innate immunity and thus, late or inefficient adaptive immunity. The innate immune system is composed of a family of ten receptor molecules, the Toll-like Receptors (TLR1-TLR10), which act as sentries to identify invaders and signal the alarm to mobilize the body's array of immune defenses.
Within the tumor lesion, there may be infiltrating monocytes, dendritic cells and leukocytes in general, that have the capability to mobilize an adaptive or innate immune response but they are either silent or immune suppressive in the absence of select immune interventions. Such infiltrating non-cancerous immune cells may express TLR3, other TLRs, RIG-I and/or MDA-5. In addition, within tumor lesions, there may be cancerous cells or stromal cells or cancer stem cells which express TLR3, other TLRs, RIG-I and MDA-5 (representing RNA-sensing molecules).
Cancer stem cells are thought to play a role in a tumor's resistance to therapy. While significant progress has been made in developing cancer therapies that result in cytoreduction and thus tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies.
MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of liver stem cells. The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells.
Double stranded RNA provides a therapeutic avenue for cancer treatment through (a) activating intra-tumoral leukocytes, abrogating their immune suppressive activity and/or (b) interacting with cancerous cells and directly inducing apoptosis, or indirectly through mobilization of immune effector mechanisms.
MCT-465 is a high molecular weight synthetic dsRNA (polya:polyU)(polya:of 70bps) with immune enhancing properties. The mechanism of action of MCT-465 is pleiotropic and mediated by RNA sensors - such as TLR3, 7/8, MDA-5 and RIG-I - expressed by antigen presenting cells and select cases, by tumor cells:
Induction of pro-inflammatory, immune enhancing cytokines locally and systemically;
Anti-angiogenic effects through a local exposure to IL-12 / IFNgamma;
In select cases, direct pro-apoptotic anti-tumoral effect.
Prior studies with similar compounds support a strong immune enhancing effect of MCT-465, consisting in generation of Tc immunity against tumors, when administered as a companion to a vaccine. This raises the possibility that MCT-465 is an effective adjunctive therapy to any small molecule targeted therapy (such as tyrosine kinase inhibitors - TKIs) that results in release of endogenous tumor antigen while interfering minimally with the immune competence.
MCT-485 is a low molecular weight synthetic dsRNA (polya:polyU of 5bps) with direct tumor cytolytic properties. The mechanism of action of MCT-485 is pleiotropic yet distinct from that of MCT-465:
Induction of tumor cell death upon direct exposure, while normal cells are minimally affected.
Production of TNF-alpha by cancer cells resulting in amplified tumor cell death and a localized immune reaction that has the potential to generalize and curb progression of metastatic cancer.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2011, and all of MultiCell's quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE MultiCell Technologies, Inc.
Report TOS
:) Robert, I agree with you 100 percent.
Simon... May I ask a question....Why are you even here? This is not a pinky stock... This stock is OTC. Which means this stock is legitimate, reports all aspects of company, better value.
Showing steps SNDY is taking since July for new persons on the board.
I agree Jim. This is a legitimate company, with legitimate products.
Remember this is not a pinky stock where the company does not report what they are doing. MCT is a OTC stock that does report what they are doing. This is a huge difference!
The only reasons why a person posts negative comments:
To short a stock. Meaning they are betting against it.
Trying to get the stock to go lower so they can buy on the cheap.
They didn't get in at the start of the run.
This is not a pinky stock. It's OTC. That's a better level and a better value for a stock.
This link is for this year.
Why sell out on this level, when a person can hold for greater profits?
I'm a SNDY long. I know this is a legitimate stock with legitimate products. I believe in SNDY 100 percent. Its taking all the correct steps necessary to move this company forward.
:) I agree Common Cents, this was a Jamming close.
:) I agree
King oil, MultiCell does also operate THREE subsidiaries. Read the MCET company overview.
Knowing that it is a OTCQB, fully reporting SEC company ( not a pink). It's # 10 on the BREAK OUT boards. This is a steal! Im definitely investing in this company.
Horseshoe I agree.
I agree. For me it's a long term hold. I still remember one stock I held for a year at .015, quadruple my profits.
This bull is ready to run up, up , up!
Side note. I just realized how I came up with my username jamming 1. It was back in the 50s, when we used to play in a band , in a garage. We were jamming! Lol times have changed. Been playing stocks since the 50s. Had to go to a broker back in the day. I became a stock broker in the 70s.